Pasireotide (diaspartate)

Modify Date: 2024-01-06 12:49:46

Pasireotide (diaspartate) Structure
Pasireotide (diaspartate) structure
 Common Name Pasireotide (diaspartate)
CAS Number 1421446-02-7 Molecular Weight 1313.41
Density N/A Boiling Point N/A
Molecular Formula C66H80N12O17 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Pasireotide (diaspartate)


Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity[1][2].

 Names

Name Pasireotide (diaspartate)

 Pasireotide (diaspartate) Biological Activity

Description Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity[1][2].
Related Catalog
Target

pKi: 8.2 (sst1), 9.0 (sst2), 9.1 (sst3), <7.0 (sst4), 9.9 (sst5)[1]

In Vitro Pasireotide diaspartate exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively)[1]. Pasireotide diaspartate effectively inhibits the growth hormone releasing hormone (GHRH) induced growth hormone (GH) release in primary cultures of rat pituitary cells, with an IC50 of 0.4 nM[1].
In Vivo Pasireotide (160 mg/kg/mouth; s.c. for 4 months) diaspartate significantly decreases the serum insulin, increases serum glucose, reduces the tumor size and increases apoptosis in Pdx1-Cre[2]. Pasireotide (2-50 μg/kg; s.c. twice daily for 42 days) diaspartate exerts the antinociceptive and antiinflammatory actions via the SSTR2 receptor in a mouse model of immune-mediated arthritis[3]. Animal Model: 12 month-old conditional Men1 knockout mice with insulinoma[2] Dosage: 160 mg/kg/mouth Administration: S.c. every month for 4 months Result: Decreased the serum insulin from 1.060 μg/L to 0.3653 μg/L and increased the serum glucose from 4.246 mM to 7.122 mM. Significantly reduced the tumor size and increased apoptosis.
References

[1]. Lewis I, et, al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun 5;46(12):2334-44.

[2]. Quinn TJ, et, al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152(6):1068-77.

[3]. Imhof AK, et, al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63(8):2352-62.

 Chemical & Physical Properties

Molecular Formula C66H80N12O17
Molecular Weight 1313.41
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Pasireotide (diaspartate) suppliers

Pasireotide (diaspartate) price

Related Compounds: More...
Pasireotide diaspartate
820232-50-6
pasireotide
396091-73-9
Pasireotide Acetate
396091-76-2
Pasireotide L-aspartate salt
396091-77-3
Pasireotide Pamoate
396091-79-5
amphotericin B 2-morpholinoethyl amide diaspartate
130176-10-2
(2S)-2-aminobutanedioate,iron(2+)
75802-64-1
(2S)-2-aminobutanedioic acid,(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol
196225-33-9
Chemsrc provides Pasireotide (diaspartate)(CAS#:1421446-02-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Pasireotide (diaspartate) are included as well.>> amp version: Pasireotide (diaspartate)

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved